The antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF. Tobramycin is an aminoglycoside antibiotic indicated for the treatment of serious bacterial ...

-Antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF COLUMBIA, S.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) announced that the ...

-Antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF COLUMBIA, S.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose ) announced that ...

COLUMBIA, S.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of ...

When a German manufacturer of blow-fill-seal (BFS) equipment for sterile pharmaceutical products looked to expand into the United States three decades ago, it initially considered a California site, ...

Since its founding in 1995, The Ritedose Corporation has evolved from a small-scale operation into one of the world’s leading specialists in Blow-Fill-Seal (BFS) technology, a platform increasingly ...

Expanded microbiology lab and analytical chemistry capabilities position Ritedose for accelerated growth. $17+ million investment fuels innovation and scale in drug development. COLUMBIA, S.C., Sept.

COLUMBIA, S.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation is investing more than $17 million to further its in-house cGMP laboratory capabilities by expanding its analytical ...

Ritedose is growing in laboratory and drug development capacity - with the announcement of a $17M in-house cGMP laboratory, expected to open in early 2026. Expanded microbiology lab and analytical ...

COLUMBIA, S.C., June 18, 2025 /PRNewswire/ -- The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution and ...